Robust metabolic pipeline focused on NASH and rare metabolic diseases

Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases.

The Company also has one product, TWYMEEG® (Imeglimin), approved in 2021, now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma, and expects to receive royalties and sales-based payments.

VIEW OUR CANDIDATES

Latest News

Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update

TWYMEEG sales in Japan for Sumitomo Pharma Fiscal Year 20221 exceeded guidance2 by more than 20%, and TWYMEEG’s FY 2023 forecast3 from Sumitomo Pharma would represent a 90% increase over the prior year sales Cash…

Read this Press Release: Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update

Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic…

Read this Press Release: Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023

Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales

TWYMEEG sales in Japan for Sumitomo Pharma Fiscal Year 20221 reached JPY 2.2 billion2 (EUR 15.0 million)3, exceeding guidance4 by more than 20% TWYMEEG’s Fiscal Year 20235 forecast of JPY 4.2 billion2 (EUR 28.9…

Read this Press Release: Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

An expertise focused on targeting mitochondrial dysfunction

The Company’s most advanced clinical products - PXL065, PXL770 and Imeglimin (now commercialized in Japan) - address significant targets in the energy metabolism pathways

View Our Candidates
An expertise focused on targeting mitochondrial dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams combines the know-how and experience to successfully develop products, such as Imeglimin, which is marketed by our partner Sumitomo Pharma in Japan since 2021.

Meet Our Team
Backed by Strong Leadership